Key Highlights
- ZBIO shares traded up 10.97% to $29.64, versus a prior close of $26.71.
- Morgan Stanley started coverage at Equalweight with a $32 target.
- Phase 3 INDIGO extension data in IgG4-related disease were upbeat.
- The PDUFA date for obexelimab is May 27, 2027.
- Phase 2 multiple sclerosis data are due Thursday.
Morgan Stanley Starts Coverage and Sees Obexelimab as Approvable
Zenas BioPharma (NASDAQ:ZBIO) shares traded up 10.97% to $29.64 after Morgan Stanley started coverage at Equalweight with a $32 target, saying obexelimab looks approvable in IgG4-related disease. The initiation joined upbeat Phase 3 INDIGO extension data and a PDUFA date of May 27, 2027.
Consensus is Moderate Buy, with targets running from the mid-$40s to the mid-$50s across other firms.
Thursday's Multiple Sclerosis Data Add Near-Term Risk and Reward
Phase 2 data for obexelimab and orelabrutinib in multiple sclerosis are expected on Thursday. Obexelimab is a bifunctional CD19 by FcgammaRIIb antibody that inhibits B-cell activity without depleting the cells, while orelabrutinib is a BTK inhibitor in Phase 3 development for progressive multiple sclerosis.
Wider Losses and a History of Dilution Remain Concerns
The last quarterly loss was wider than expected, and the company has a history of dilution. Earnings per share are a loss of $8.99. Zenas has a market capitalization of about $1.93 billion and a 52-week range of $13.50 to $44.60. Volume was light.
The healthcare sector ETF is near a 52-week high, which has supported shares of clinical-stage biotech names.
PDUFA Date and Phase 2 Results Define the Road Ahead
Investors will track the multiple sclerosis readout this week and the May 27, 2027 FDA decision date. Reliance on a few assets means each data point carries weight.






Please wait processing your request...